Elevated CDK7 expression in tumor cells compared with their normal counterparts raise the possibility that tumors with increased expression of CDK7 may be more sensitive to CDK7 inhibition, particularly in the case of ER+ breast cancer, where the CDK7-activated nuclear receptor, ERα, drives tumor progression (12). The gene discussed is CDK7; the disease is breast carcinoma.